biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas